1. Introduction {#sec1}
===============

Acute ischemic stroke occurs as a result of a disturbance in the blood vessels supplying blood to the brain. In spite of improvement in health care and medical condition, the prevalence of stroke has been increasing in aging society \[[@B1]\]. It is widely recognized that stroke is one of the leading causes of mortality and morbidity in adults and the most common cause of physical disability in many areas \[[@B2]--[@B5]\]. It would leave irreversible neurological impairments and cognitive decrements to the patients. In many cases, patients suffer from distressing fatigue and long-term impairment in activities such as walking and speech, which also extends to significant emotional burden like depression \[[@B1], [@B6]\]. Further, the progression of poststroke impairments might lead to a bedridden state and dementia, which generates lots of social concerns especially in the aging societies \[[@B7]\]. Thus, medical diagnosis and health care for acute ischemic stroke patients still present a challenge for clinicians as well as the society.

However, many acute ischemic stroke victims fail to receive medical treatment in time. In fact, stroke treatments are time sensitive \[[@B8]\]. Delay in reaching medical care after stroke symptom onset is the most frequent reason for low rates of thrombolytic use. Whether individuals view their symptoms as the signal of a ischemic stroke impact the delay before hospital arrival \[[@B9]\] and the effectiveness of urgent treatment. Indeed, prompt and accurate diagnosis of ischemic stroke is critical to seek acute therapy to reverse the problem. The diagnostic classification schemes have long incorporated two types of information: clinical observation of symptoms and radiological evidence of underlying pathophysiology \[[@B10], [@B11]\]. For example, neuroimaging and analysis of cerebrospinal fluid are widely used for diagnosis of stroke besides identification of clinical features of stroke \[[@B12]\].

Meanwhile, many acute ischemic stroke patients would choose traditional Chinese treatments as an alternative medical practice in China. In fact, practitioners of TCM have long focused on the medical care of stroke \[[@B13]--[@B16]\]. And there has been a comprehensive system of stroke diagnosis, which is characterized by its unique theoretical basis and practical experience, in TCM science. Herein, the syndromes ("ZHENG" in Chinese) of stroke are described in six aspects: wind pattern (Feng Zheng), heat pattern (Huo Re Zheng), phlegm pattern (Tan Zheng), blood stasis pattern (Xue Yu Zheng), qi deficiency pattern (Qi Xu Zheng), and yin deficiency pattern (Yin Xu Zheng) \[[@B17]\]. The integrated analysis of symptoms under these patterns, such as tongue, pulse, and complexion related symptoms, leads to the identification of syndromes of stroke, which helps to determine the cause, nature, and location of the illness, the patient\'s physical condition, and the patient\'s treatment \[[@B18]\].

As assessing all of the recorded symptoms relevant to acute ischemic stroke in TCM science is time consuming and impractical clinically, it is pivotal to select core symptoms for the accurate diagnosis of syndromes of acute ischemic stroke. Some models have been proposed to generate diagnosis criteria for syndromes of stroke. Jiang et al. \[[@B19]\] developed a Bayes discriminant model for diagnosis of stroke with Qi deficiency and blood stasis syndrome. Gao et al. \[[@B20]\] established a diagnostic scale system for TCM syndromes of ischemic stroke. Both of these two studies obtained high diagnosis accuracy partly due to large samples (above 1000 samples), nevertheless, their symptom selection, which were based on expert experience to some extent, were not appropriate and rigorous. Kim et al. \[[@B18]\] applied binary logistic regression analysis with backward method on the assessed symptoms, to come up with diagnostic model for syndrome identification. The method sorted out and explained the core symptoms for each syndrome of stroke; however, it omitted the analysis of diagnosis accuracy which is the fundamental pursuit of the model. Laskowitz et al. \[[@B21]\] used correlation analysis to select significant features and developed a logistic model to evaluate the relationship between these features and acute stroke diagnosis. Lu et al. \[[@B22]\] presented a Bayesian network framework to construct a high-confidence syndrome predictor based on the optimum subset. These studies also performed well in accuracy based on selected features. In spite of the progress, few existing studies attempt to analyse the underlying mechanism of core symptoms in the molecular level, which may be responsible for their significance. Understanding the possible molecular mechanism of core symptoms would contribute to the study of syndromes. It not only helps to interpret the mechanism of action of core symptoms in the diagnosis of syndromes of stroke but also uncovers relevant biological pathways.

With the development of systems biology, it has been possible to integrate phenotype data, omics data, chemical data, pathway maps, and interactions of heterogeneous data in the study of molecular mechanism of core symptoms of TCM syndrome. In this work, we propose a two-level model ([Figure 1](#fig1){ref-type="fig"}) for the analysis of syndrome of acute ischemic stroke: from the macro level of diagnostic model to the micro level of molecular mechanism. SVM \[[@B23]\] was used to generate the diagnostic model for the syndrome of acute ischemic stroke. Meanwhile, core symptoms were chosen through organizing different groups of symptoms as the feature set of SVM model. The features that receive the best diagnostic performance are selected as the core symptoms. Next, analysis of molecular mechanism was undertaken to explore the possible way which is responsible for the significance of core symptoms. The analysis was done by two means: Pathway Pattern-based method \[[@B24]\] was used to build a multilayer correlation network that relates core symptoms to the mined Pathway Pattern; MetaDrug \[[@B25]\] was used to uncover the enriched pathways and build an interaction network to decipher the molecular basis. As the positive samples are too limited to generate diagnostic model for phlegm-heat and bowel-repletion syndrome (Tan Re Fu Shi Zheng), phlegm-heat blocking internally syndrome (Tan Re Nei Bi Zheng), phlegm-damp clouding orifices syndrome (Tan Shi Meng Shen Zheng), qi deficiency and blood stasis syndrome (Qi Xu Xue Yu Zheng), and yin-deficiency and wind-agitation syndrome (Yin Xu Feng Dong Zheng), the two-level model was suggested for the analysis of wind-phlegm collateral obstruction syndrome of acute ischemic stroke \[[@B26]\].

2. Methods {#sec2}
==========

2.1. Data Preparation {#sec2.1}
---------------------

We enrolled acute ischemic stroke patients within 72 hours after their ictus from several hospitals located in Northern China from August 2007 to December 2009. All the patients are aged between 35 and 75 without some specific predefined diseases. The diagnoses of syndromes were made by experienced doctors of TCM on the basis of \[[@B17]\]. A questionnaire of symptoms was formulated after the literature research and expert investigation. And the symptoms were observed by nerve physicians, who had been specially trained for this program, through observation, listening, interrogation, and pulse-taking along with the medical history of patients. In total, we collected 166 acute ischemic stroke samples of patients with 102 records of symptoms. Syndromes and symptoms present in the form of binary values. We omitted phlegm-heat and bowel-repletion syndrome, phlegm-heat blocking internally syndrome, phlegm-damp clouding orifices syndrome, qi deficiency and blood stasis syndrome, and yin-deficiency and wind-agitation syndrome as the number of positive samples is too limited to generate diagnostic model. Thus, we focused on the analysis of wind-phlegm collateral obstruction syndrome of acute ischemic stroke.

2.2. SVM-Based Diagnostic Model {#sec2.2}
-------------------------------

We choose SVM to generate the diagnostic model, which is essentially a classification schema, because SVM is based on strong theoretical foundations and performs well in many application domains \[[@B27]\]. As the SVM training environment, we selected the widely used libsvm software package \[[@B28]\]. We used a RBF kernel function for all the SVM classifiers to prevent the choice of kernel function from affecting our results.

As illustrated in [Table 1](#tab1){ref-type="table"}, the dataset of wind-phlegm collateral obstruction syndrome is a small and imbalanced dataset with relatively high dimension. With imbalanced data, classifiers would judge almost all instances as the majority class because classifiers are designed to generalize from sample data and output the simplest hypothesis that best fits the data \[[@B29]\]. Thus, the regular SVM-based classification scheme would determine almost all the new patients as positive instances in practice. Here, we take two steps to improve the performance of SVM-based classification scheme. Firstly, we select core symptoms from the original 102 symptoms. Then samples of the majority class are combined to address the imbalance of dataset.

### 2.2.1. Core Symptoms Selection {#sec2.2.1}

The irrelevant and redundant information in the original features would degrade the performance of learning algorithms. Feature selection is needed to extract core symptoms and remove secondary symptoms. In general, a feature is good if it is relevant to the target concept. Here information gain \[[@B30]\] is used to measure the relevance of symptoms to wind-phlegm collateral obstruction syndrome. Given a random variable *C*, we define *entropy* to measure the uncertainty of *C* as $$\begin{matrix}
{H\left( C \right) = - {\sum_{i}{P\left( \text{c}_{i} \right)\text{lo}\text{g}_{2}\left( {P\left( c_{i} \right)} \right)}},} \\
\end{matrix}$$ and the entropy of *C* after observing values of another variable *X* is defined as $$\begin{matrix}
{H\left( {C\, \mid \, X} \right) = - {\sum_{j}{P\left( \text{x}_{j} \right){\sum_{i}{P\left( {c_{i}\, \mid \, x_{j}} \right)\text{lo}\text{g}_{2}\left( {P\left( {c_{i}\, \mid \, x_{j}} \right)} \right)}},}}} \\
\end{matrix}$$ where *P*(*c* ~*i*~) is the prior probabilities for all values of *C*, and *P*(*c* ~*i*~ \| *x* ~*j*~) is the posterior probabilities of *C* given the values of *X*. Then the information gain for *C* and *X* is given later to reflect the additional information about *C* provided by *X*: $$\begin{matrix}
{IG\left( {C\, \mid \, X} \right) = H\left( C \right) - H\left( {C\, \mid \, X} \right).} \\
\end{matrix}$$ Here we choose syndrome as the random variable *C* and symptom as *X*. Thus the information gain between each symptom and the syndrome can be calculated to rank the significance of symptoms.

To extract the core symptoms, different groups of symptoms, whose information gains are above a chosen threshold, are used to train the SVM-based classification scheme. As classifiers can obtain a high accuracy in imbalanced cases which is meaningless, we randomly choose ten positive samples and ten negative samples to constitute the test set, while the rest 110 positive samples and 36 negative samples constitute the training set. For each group of symptoms, the experiment is repeated for 100 times and an average accuracy of prediction in test set is calculated. Finally, the group of symptoms that obtain the highest accuracy is regarded as the core symptoms.

### 2.2.2. Pairwise Undersampling {#sec2.2.2}

SVM would be ineffective in determining the class boundary and produce suboptimal classification models when the training instances are imbalanced. And the performance would drop significantly accordingly. Given a set of labelled instances *X* ~train~ = {*x* ~*i*~, *y* ~*i*~}~*i*=1~ ^*n*^ and a kernel function *K*, SVM finds the optimal *α* ~*i*~ for each *x* ~*i*~ to maximize the margin between the hyperplane and the closet instances to it. The class prediction function for a new test instance *x* is formulated as $$\begin{matrix}
{{sign}\left( {f\left( x \right) = {\sum_{i = 1}^{n}{y_{i}\alpha_{i}K\left( {x,x_{i}} \right) + b}}} \right).} \\
\end{matrix}$$ The instances having nonzero *α* ~*i*~ values are called support vectors. In the case of wind-phlegm collateral obstruction syndrome, the positive support vectors outnumber the negative support vectors as a result of the imbalance of the dataset. According to the prediction function, the diagnosis of a new patient is likely to be dominated by positive support vectors and produce a positive prediction.

Here we introduce a strategy of pairwise undersampling to overcome the imbalance. In general, two samples which are similar to each other in core symptoms are merged into one. Given two samples *X* and *Y*, Euclidean distance is used to define the similarity between them as later: $$\begin{matrix}
{{dist} = \left. ||{X - Y} \right.||^{1/2}.} \\
\end{matrix}$$ The Euclidean distances were computed for all possible combinations of two samples from the dataset. Then by ranking the Euclidean distances, we got to learn the rough distribution of the samples. The combination with a smaller Euclidean distance, representing a closer similarity, got a higher ranking, and combinations with the same Euclidean distance were ranked randomly. Afterwards, we traversed the ranking and merged the two samples whose Euclidean distance is below a predefined distance threshold. The new sample was generated by averaging the two samples in the combination. It should be noted that each sample can be merged for just once in case of loss of information; in other words, combinations cannot be used for mergence if they contain samples that have been processed already. Finally, the SVM model, generated from the training set after pairwise undersampling, was applied to classify the samples in the test set.

During the implementation, a proper Euclidean distance threshold should be selected for pairwise undersampling. In fact, threshold on the high side would merge the samples excessively and cause loss of information, while threshold on the low side leads to deficient mergence and barely satisfactory improvement of the prediction performance. Thus, we set different distance thresholds to generate several SVM models. For each Euclidean distance threshold, the experiment is repeated for 100 times, and an average accuracy of prediction in the test set is calculated. The SVM model that obtains the highest accuracy is selected.

To measure the performance of SVM-based classification scheme, we introduce the metric of G-mean \[[@B31]\], which is defined as $$\begin{matrix}
{g = \sqrt{\text{sen} \times \text{spe}},} \\
\end{matrix}$$ where sen = sensitivity, spe = specificity. This metric has been used for evaluating classifiers on imbalanced datasets. We also use this metric to evaluate our model. Besides, we list the sensitivity and specificity separately to present a more detailed description of the diagnostic model.

2.3. Molecular Mechanism Analysis {#sec2.3}
---------------------------------

Apart from generating diagnostic model for wind-phlegm collateral obstruction syndrome based on the core symptoms, we also attempt to shed light on the molecular basis of the significance of core symptoms for the purpose of a better understanding of the syndrome. The analysis of molecular mechanism is undertaken by Pathway Pattern-based method \[[@B24]\] and MetaDrug platform \[[@B25]\], respectively, to correlate symptoms with Pathway Pattern, uncover enriched pathways and construct the most relevant interaction network. By referring to the Human Phenotype Ontology (HPO) \[[@B32]--[@B34]\], we bridged the gap between symptoms and genes. Firstly, we searched the ontology file for HPO terms which describe phenotypic abnormalities that have similar meaning with the core symptoms. For example, three HPO terms, namely, "Somnolence" (HP:0001262), "Drowsiness" (HP:0002329), and "Paroxysmal drowsiness" (HP:0002330), were found to have similar meaning with the core symptom of "drowsiness." Then associated genes of each HPO term were retrieved from phenotype-genes association file in HPO database. Thus, the associated genes of the three HPO terms previously mentioned might be responsible for the symptom of "drowsiness."

### 2.3.1. Multilayer Correlation Network Relating Core Symptoms with Pathway Pattern {#sec2.3.1}

Pathway Pattern \[[@B24]\] is extracted to reflect the biological features of core symptoms. We collected HPO terms for all of the core symptoms. Then associated genes of these HPO terms were retrieved and sorted according to their number of occurrences. Some occasionally occurring genes were removed from further analysis. And as to the remaining genes, we designate them as "relevant genes" hereinafter as the molecular mechanism analysis of core symptoms is based on these genes. Next, we prepared pathway information for the relevant genes by searching the KEGG database \[[@B35]\], where we could search for all pathways that a specific gene is involved. This resulted in a pathway dataset in which each record of pathways corresponds to one specific gene. The pathway dataset was used to extract the Pathway Pattern, which is in the form of association rules, with data mining method described in \[[@B24]\].

Then we related core symptoms with the extracted Pathway Pattern in the reverse direction. A gene is connected with an association rule of the Pathway Pattern if the gene contains all the pathways of the association rule in its related pathways. Similarly, a core symptom is connected with a gene if the gene exists in the associated genes of the HPO terms that have similar meaning with this symptom. In this way, a symptom-gene-pathway multilayer correlation network was constructed using Cytoscape \[[@B36]\] to discover the molecular explanation for core symptoms.

### 2.3.2. Enriched Pathways {#sec2.3.2}

On the basis of the relevant genes, we uncovered enriched pathways in MetaDrug platform \[[@B25]\]. A *P* value is assigned to each pathway to indicate the statistical significance of the enrichment. The enriched pathways are ranked by −log⁡⁡(*P*  value).

### 2.3.3. Most Relevant Interaction Network {#sec2.3.3}

The relevant genes were used as the input list for the generation of relevant biological networks in MetaDrug. The algorithm for generating the networks was chosen as Analyze Networks algorithm. The Z-score, G-score, and *P*  value \[[@B37]\] are three different scoring functions used to rank the small networks. The Z-score ranks the networks according to saturation with the objects from the input list of seed nodes. The G-score modifies the Z-score based on the number of Canonical Pathways used to build the network. If a network has a high G-score, it is saturated with expressed genes (from Z-score), and it contains many Canonical Pathways. The *P*  value, which is calculated using the basic formula for hypergeometric distribution, essentially represents the probability for a particular mapping of a gene list to a network to arise by chance, considering the numbers of genes in the gene list versus the number of genes in the network. In principle, all the biological networks constitute the interaction network of input genes. However, as the interaction network built from all of the gene nodes might be too large to present; here we use the the *P*  value to prioritize the biological networks and select the top ranked network as the most relevant interaction network of the input genes, which helps to decipher the molecular basis of core symptoms.

3. Results {#sec3}
==========

3.1. Core Symptoms Selection {#sec3.1}
----------------------------

Information gains were computed for all of the 102 symptoms on the wind-phlegm collateral obstruction syndrome. Some severely imbalanced symptoms might also obtain high information gains; nevertheless, these symptoms are likely to be valueless in classification. For example, we cannot trust a symptom whose three negative instances all lead to negative outcome because these three negative instances are too few to be convincing. In the extreme situation, these three negative instances might all be divided into the test set. Here we set a threshold of 5 to remove the severely imbalanced symptoms whose minority is less than 5. In this way, 62 symptoms were left for further analysis. [Table 2](#tab2){ref-type="table"} presents the information gains for these symptoms after sorted.

Different thresholds were chosen based on the sorted information gains to select symptoms for the training of classification scheme. Some thresholds were omitted as the selected symptoms did not change much. As illustrated in [Figure 2](#fig2){ref-type="fig"}, when the threshold is set as 0.004, the classification scheme obtains the best prediction performance in test set with fewer symptoms. As a result, the 24 symptoms whose information gains are above 0.004 are selected as the core symptoms.

3.2. Pairwise Undersampling {#sec3.2}
---------------------------

As illustrated in [Figure 3](#fig3){ref-type="fig"}, the original classification scheme predicts almost all the patients as the positive instances, leading to a sensitivity close to 1 and a specificity close to 0. With selection of core symptoms, the accuracy increases because of improvement in specificity. Nevertheless, the specificity is still quite low with a median of 0.2. Thus, pairwise undersampling is needed to address the imbalance and improve specificity.

Euclidean distances were computed based on the core symptoms for all possible combinations of two samples. Next, the Euclidean distances were ranked to describe the closeness of samples. We set different thresholds to combine two similar samples, which were then replaced by their average. As shown in [Figure 4](#fig4){ref-type="fig"}, the accuracy of classification scheme gradually increases before distance threshold = 8. Then it begins to decrease because of excessive undersampling, which leads to loss of information. When distance threshold = 8, the classification scheme obtains the highest accuracy = 66.55%. In this case, the 110 positive samples were decreased to 58 positive samples, where 52 pairs of close samples were combined and the other six samples were left alone. When distance threshold = 10, all of the 110 positive samples have been combined once, resulting in 55 positive samples left.

To reveal the change of performances of classification schemes, the distribution and tendency of sensitivity and specificity of different models are demonstrated in [Figure 5](#fig5){ref-type="fig"}. We could find that specificity gradually increases with the undersampling of positive samples before distance threshold = 8. Although sensitivity decreases, it is insignificant compared with the improvement in specificity. After distance threshold = 8, specificity becomes steady while sensitivity keeps on decreasing.

Further, the metric of G-mean, which has been used for evaluating classifiers on imbalanced datasets, was utilized to measure the performance of SVM-based diagnostic model. As illustrated in [Figure 6](#fig6){ref-type="fig"}, the G-mean of the diagnostic model increases from 0.1253 to 0.4258 after the selection of core symptoms. Then it increases again after pairwise undersampling. When distance threshold = 8, the diagnostic model obtains the highest G-mean of 0.6483, which is acceptable considering the performance of classifiers on datasets of comparable size in \[[@B27], [@B29]\].

3.3. Multilayer Correlation Network Relating Core Symptoms with Pathway Pattern {#sec3.3}
-------------------------------------------------------------------------------

We retrieved as many HPO terms as possible for each core symptom manually. For example, as to the symptom "Drowsiness", we searched the database by keyword "drowsiness" and other synonyms like "somnolence," and found three HPO terms which convey similar meaning: "Drowsiness" (HP:0002329), "Somnolence" (HP:0001262), and "Paroxysmal drowsiness" (HP:0002329). As shown in [Table 3](#tab3){ref-type="table"}, most core symptoms have several corresponding HPO terms, while some core symptoms, related with pulse and fur, are not included in the database. The HPO terms were arranged to eliminate redundancy. In total, 43 different HPO terms were found.

Then associated genes of the 43 HPO terms were retrieved and sorted according to their number of occurrences. In total, 775 different genes were retrieved, of which POLG (Entrez Gene ID: 5428) occurs for 12 times and ranks the first, while 353 different genes occur only once and come last. Genes whose occurrences are below 3 are regarded as occasionally occurring genes and are removed from further analysis. As a result, 251 genes were remained and constituted the relevant genes. Next, we prepared pathway information for the relevant genes through searching the KEGG database. As some genes have no pathway information in the KEGG database, the number of records in the pathway dataset is reduced to 159. Based on the pathway dataset, the Pathway Pattern was extracted through bidirectional association rule mining (support = 0.055, confidence = 0.800) to reflect the biological features of core symptoms. As shown in [Table 4](#tab4){ref-type="table"}, the Pathway Pattern is made up of thirteen 1-item association rules, six 2-item association rules, four 3-item association rules, and one 4-item association rule.

In the reverse direction, we related the extracted Pathway Pattern with the 251 relevant genes and then related these genes with the 24 core symptoms. It should be noted that only complete symptom-gene-pathway interactions are maintained to correlate core symptoms with the Pathway Pattern. In other words, a node is removed if it is isolated; an edge is removed if it terminates at the gene node. In this way, a symptom-gene-pathway multilayer correlation network was formulated as [Figure 7](#fig7){ref-type="fig"}. It contains 15 symptom nodes, 98 gene nodes, and 24 pathway nodes. The correlation network helps to discover the molecular explanation for core symptoms.

3.4. Enriched Pathways {#sec3.4}
----------------------

The 251 relevant genes were used as the input list for the enrichment analysis by pathway maps in MetaDrug. The enriched biological pathways in [Figure 8](#fig8){ref-type="fig"} might be responsible for the role of core symptoms in the diagnosis of syndrome of acute ischemic stroke. The relevance of some pathways has been demonstrated in previous literature. Acute oxidative phosphorylation ([Figure 9](#fig9){ref-type="fig"}) defect may have a crucial role in the pathophysiology of stroke-like episodes. The transfer RNA of leucine mtDNA mutation decreases protein synthesis and causes oxidative phosphorylation failure, leading ultimately to adenosine triphosphate depletion and energy failure \[[@B38], [@B39]\]. Low level of low-density leucine, isoleucine, and valine ([Figure 10](#fig10){ref-type="fig"}) is a characteristic of the plasma of stroke patients \[[@B40]\]. Besides, urea cycle disorder ([Figure 11](#fig11){ref-type="fig"}), which is among the top 20 enriched pathways, is also known to be unusual causes of stroke in some cases \[[@B41]\].

3.5. Most Relevant Interaction Network {#sec3.5}
--------------------------------------

We generated relevant biological networks in MetaDrug on the basis of the 251 relevant genes. The number of nodes in a network is set as 100. As shown in [Figure 12](#fig12){ref-type="fig"}, the most relevant biological network obtains the highest *P* value of 2.66e-37. It contains 25 input genes and one fragment of canonical pathway from IL-6 to STAT2. Some of the input genes, namely, B-Raf, ALK-1, Endoglin, PPARgamma fusion protein, and SOX 10, are significantly upregulated. The biological network helps to explore the molecular basis of core symptoms.

4. Discussion {#sec4}
=============

In this work, we propose a two-level model for the analysis of syndrome of acute ischemic stroke. The novel method is applied in the case of wind-phlegm collateral obstruction syndrome of ischemic stroke. The two-level model not only selects core symptoms to generate the SVM-based diagnostic model of wind-phlegm collateral obstruction syndrome but also uncovers the underlying mechanism of core symptoms in the molecular level. The molecular mechanism analysis, which contributes to the study of syndrome, is undertaken in three complementary aspects: a symptom-gene-pathway multilayer correlation network is constructed to relate core symptoms with the Pathway Pattern; enriched pathways are revealed which might be responsible for the significance of core symptoms; most relevant interaction network is generated to decipher the molecular basis of core symptoms.

We demonstrated the framework of the two-level model by using 166 acute ischemic stroke samples of patients on wind-phlegm collateral obstruction syndrome with 102 symptoms. We showed the process of the generation of diagnostic model. To begin, information gain was computed for each symptom to decide the relevance of symptoms to the syndrome. Different information gains were then used to choose symptoms for the training of SVM-based classification schemes. The group of symptoms which yielded the best classification scheme was selected as the core symptoms. Owing to the imbalance of dataset, the classification scheme performs poorly in predicting negative instances. Through pairwise undersampling, we combined pairs of samples which are close in Euclidean space. A proper distance threshold was chosen to combine the samples in case of excessive or deficient mergence. After these procedures, we generated the SVM-based diagnostic model, which improved the accuracy and G-mean of the prediction. On the basis of core symptoms, the diagnostic model could be used to predict the wind-phlegm collateral obstruction syndrome for acute ischemic stroke patients.

Next, we demonstrated the flow of molecular mechanism analysis to account for the significance of core symptoms. To bridge the gap between core symptoms and genes, we searched the HPO database for synonymous phenotypic terms and retrieved genes associated with these HPO terms. Then the mechanism analysis was carried out by Pathway Pattern-based method and MetaDrug platform in three complementary aspects. Pathway Pattern-based method was used to build a symptom-gene-pathway multilayer correlation network. The Pathway Pattern was extracted by mining the KEGG pathway entries of relevant genes, which are related with core symptoms. In the reverse direction, the Pathway Pattern, genes, and core symptoms were connected to generate the multilayer correlation network, which presents a new view of the relationship between symptoms and pathways. Additionally, MetaDrug platform was used to reveal the enriched pathways and construct the relevant interaction network. The enrichment analysis by pathway maps was based on the relevant genes. Some of the enriched pathways have been demonstrated to play a role in the pathophysiology of stroke in previous literature. Further the relevant genes were utilized as the seed nodes for construction of relevant biological network. The subnetwork that obtained the highest *P* value was selected as the most relevant interaction network to decipher the molecular basis of core symptoms. In combination, the analysis of molecular mechanism sheds light on the underlying mechanism for the significance of core symptoms and contributes to a better understanding of wind-phlegm collateral obstruction syndrome.

The two-level model is a new attempt to extend the analysis of TCM syndromes. Previous research has mainly focused on building up diagnostic models for accurate prediction of TCM syndromes based on selected symptoms. The two-level model moves one step forward to analyse the mechanism of selected core symptoms in the molecular level. It combines the generation of diagnostic model with the analysis of molecular mechanism of core symptoms.

Certainly, there are some limitations in our method. Firstly, this study takes only one syndrome of acute ischemic stroke into consideration because of the small and imbalanced dataset. This would affect the reliability and usefulness of the method. Our future work would collect more samples for a comprehensive research on the syndromes of acute ischemic stroke. Secondly, our method can suffer from annotation bias which is also the limitation of most functional annotation-based methods. Associated genes of impulse-related and fur-related symptoms need to be added in future work. Thirdly, laboratory or radiological evidence could be taken into consideration in the future in order to generate more accurate diagnostic model.

In summary, this work demonstrates that integration of diagnostic model and molecular mechanism analysis creates an interesting perspective for better understanding of TCM syndromes. It not only makes a contribution to the research on syndrome classification but also provides insights into the molecular mechanism of the significance of core symptoms of syndrome. It would provide a new opportunity for the study of TCM syndromes.
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![The framework of the two-level model for analysis of syndrome of acute ischemic stroke. Firstly, a diagnostic model of syndrome is generated based on selected core symptoms in the macro level. Then molecular mechanism analysis of core symptoms in the micro level is undertaken to shed light on the molecular basis of the significance of core symptoms.](ECAM2013-293010.001){#fig1}

![The accuracies of classification schemes based on different groups of symptoms. Symptoms whose information gains are above the threshold are selected. The black line indicates accuracies of models based on different groups of symptoms, which helps to select core symptoms. The red line presents the accuracy of the original classification scheme without feature selection as a comparison.](ECAM2013-293010.002){#fig2}

![Distribution of sensitivity and specificity. Blue boxes indicate the distribution for the original classification scheme without feature selection. Green boxes indicate the distribution for the classification scheme based on core symptoms.](ECAM2013-293010.003){#fig3}

![The accuracies of classification schemes after pairwise undersampling. Two samples whose Euclidean distance is below the threshold are combined. The black line indicates accuracies of models after pairwise undersampling based on different distance thresholds. The red line presents the accuracy of the original classification scheme based on core symptoms without undersampling as a comparison.](ECAM2013-293010.004){#fig4}

![Distribution and tendency of sensitivity and specificity. (a) Boxes of different colours indicate distribution for classification schemes with different thresholds of Euclidean distances. (b) Black and red lines indicate the tendency of sensitivity and specificity, respectively, which is calculated by averaging the 100 experiments.](ECAM2013-293010.005){#fig5}

![G-means for classification schemes with different distance thresholds. Black bars indicate G-mean for the original classification scheme without feature selection. Red bars indicate the rise in G-mean for classification scheme based on core symptoms. Blue bars indicate the rise in G-mean for classification schemes after pairwise undersampling.](ECAM2013-293010.006){#fig6}

![Symptom-gene-pathway multilayer correlation network. Symptom nodes are labelled with names of core symptoms. Gene nodes are labelled with gene names. Pathway nodes are labelled with symbols of the association rules of pathway pattern, which has been specified in [Table 4](#tab4){ref-type="table"}.](ECAM2013-293010.007){#fig7}

![Enrichment Analysis by Pathway Maps. A *P* value is assigned to each pathway and the pathways are ranked by −log⁡(*P*   value).](ECAM2013-293010.008){#fig8}

![The pathway map of oxidative phosphorylation. Hexagons indicate input genes (e.g., NDUFA1, NDUFB3).](ECAM2013-293010.009){#fig9}

![The pathway map of leucine, isoleucine, and valine metabolism. Hexagons indicate input genes (e.g., MCC, IVD).](ECAM2013-293010.010){#fig10}

![The pathway map of urea cycle. Hexagons indicate input genes (e.g., NAGS, CPSM).](ECAM2013-293010.011){#fig11}

![Most relevant interaction network. Thick cyan lines indicate the fragments of canonical pathways. Upregulated input genes are marked with red circles (e.g., B-Raf, PMP22).](ECAM2013-293010.012){#fig12}

###### 

Samples of wind-phlegm collateral obstruction syndrome.

  Dataset                                       Positive   Negative   Total   Ratio      Features
  --------------------------------------------- ---------- ---------- ------- ---------- ----------
  Wind-phlegm collateral obstruction syndrome   120        46         166     2.61 : 1   102

###### 

Information gains for the remaining 62 symptoms.

  Symptom                               Information gain
  ------------------------------------- ------------------
  Greasy fur                            0.041751
  Thready pulse                         0.032381
  Sublingual vein bruising              0.030248
  Deep pulse                            0.029555
  Slippery pulse                        0.023376
  Taut pulse                            0.022498
  Drowsiness                            0.020716
  Red tongue                            0.02046
  Dark purple lips                      0.015375
  Excessive salivation                  0.014193
  Dim complexion                        0.013139
  Heat in the palms and soles           0.013014
  Headache                              0.013014
  Dizziness                             0.010641
  Fatigue                               0.009921
  Dry stool and oliguria                0.009029
  Emotional lability                    0.008032
  Timid low voice                       0.006736
  Constipation                          0.005297
  Numbness                              0.004979
  Thick fur                             0.004949
  High-pitched, coarse voice            0.004901
  Limb limp                             0.004516
  Vomiting                              0.004181
  Night sweat                           0.003487
  Red face and eyes                     0.003487
  Limbs twitching                       0.00335
  Hand, foot swelling                   0.00335
  Pale tongue                           0.00335
  Plump tongue                          0.00333
  Purplish tongue                       0.003244
  Shortness of breath                   0.003108
  Thin fur                              0.002897
  Dull expression                       0.002566
  Yellow fur                            0.002244
  Spasm of nape                         0.001819
  Aching and weakness                   0.001818
  Sweat when quite                      0.001461
  Wry tongue                            0.001401
  Poor appetite                         0.00134
  Dark tongue                           0.001255
  Fatigue and drowsiness                0.001208
  Pale red tongue                       0.001147
  Restless                              0.000649
  Sticky phlegm                         0.000649
  Uneven pulse                          0.000649
  Overweight                            0.000615
  Vexation and irritability             0.000577
  Fever                                 0.000412
  Palpitate                             0.000369
  Pale complexion                       0.000137
  Dry stool and constipation            4.85*E* − 05
  Apathy                                3.93*E* − 05
  White fur                             1.83*E* − 05
  Bitter taste in the mouth             1.72*E* − 05
  Reddish yellow urine                  1.17*E* − 05
  Tinnitus                              1.06*E* − 05
  Pale tongue                           1.06*E* − 05
  Sweat after little movement           5.33*E* − 06
  Dark purple lips and dim complexion   5.33*E* − 06
  Ecchymosis on tongue                  4.92*E* − 06
  Predilection for cold drink           1.96*E* − 07

###### 

Corresponding HPO terms for core symptoms.

  Core symptom                  HPO terms
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Greasy fur                    Smooth tongue (HP:0010298)
  Thready pulse                 None
  Sublingual vein bruising      Abnormality of oral frenula (HP:0000190), tongue nodules (HP:0000199), glossitis (HP:0000206), and tongue telangiectasia (HP:0000227)
  Deep pulse                    None
  Slippery pulse                None
  Taut pulse                    None
  Drowsiness                    Somnolence (HP:0001262), drowsiness (HP:0002329), and paroxysmal drowsiness (HP:0002330)
  Red tongue                    Tongue telangiectasia (HP:0000227)
  Dark purple lips              Thick lower lip vermilion (HP:0000179), pursed lips (HP:0000205), lip telangiectasia (HP:0000214), thick upper lip vermilion (HP:0000215), and lip freckle (HP:0010798)
  Excessive salivation          Abnormality of parotid gland (HP:0000197), drooling (HP:0002307), excessive salivation (HP:0003781), abnormality of the salivary glands (HP:0010286), and abnormality of salivation (HP:0100755)
  Dim complexion                Pallor (HP:0000980), dull facial expression (HP:0008769)
  Heat in the palms and soles   Palmoplantar hyperhidrosis (HP:0007410)
  Headache                      Migraine (HP:0002076) and headache (HP:0002315)
  Dizziness                     Vertigo (HP:0002321)
  Fatigue                       Syncope (HP:0001279), muscle weakness (HP:0001324), generalized muscle weakness (HP:0003324), and fatigable weakness (HP:0003473)
  Dry stool and oliguria        Constipation (HP:0002019) and oliguria (HP:0100520)
  Emotional lability            Emotional lability (HP:0000712) and mood swings (HP:0000720)
  Timid low voice               Abnormally low-pitched voice (HP:0010300) and weak cry (HP:0001612)
  Constipation                  Constipation (HP:0002019)
  Numbness                      Impaired vibratory sensation (HP:0002495) and reduced consciousness/confusion (HP:0004372)
  Thick fur                     None
  High-pitched, coarse voice    High-pitched, coarse voice (HP:0008377)
  Limb limp                     Distal muscle weakness (HP:0002460), limb muscle weakness (HP:0003690), and proximal muscle weakness (HP:0003701) and lower limb muscle weakness (HP:0007340)
  Vomiting                      Vomiting (HP:0002013) and nausea and vomiting (HP:0002017)

###### 

Pathway pattern underlying core symptoms.

  Symbol   Pathway entry                            Pathway description                                                                                count
  -------- ---------------------------------------- -------------------------------------------------------------------------------------------------- -------
  1a       hsa01100                                 Metabolic pathways                                                                                 57
  1b       hsa04151                                 PI3K-Akt signaling pathway                                                                         16
  1c       hsa05200                                 Pathways in cancer                                                                                 16
  1d       hsa05010                                 Alzheimer\'s disease                                                                               13
  1e       hsa04010                                 MAPK signaling pathway                                                                             13
  1f       hsa05016                                 Huntington\'s disease                                                                              12
  1g       hsa04510                                 Focal adhesion                                                                                     12
  1h       hsa00280                                 Valine, leucine, and isoleucine degradation                                                        11
  1i       hsa05012                                 Parkinson\'s disease                                                                               11
  1j       hsa00190                                 Oxidative phosphorylation                                                                          11
  1k       hsa04974                                 Protein digestion and absorption                                                                   10
  1l       hsa03010                                 Ribosome                                                                                           9
  1m       hsa04810                                 Regulation of actin cytoskeleton                                                                   9
                                                                                                                                                       
  2a       hsa05012; hsa05016                       Parkinson\'s disease and Huntington\'s disease                                                     11
  2b       hsa05010; hsa05012                       Alzheimer\'s disease and Parkinson\'s disease                                                      11
  2c       hsa00190; hsa05010                       Oxidative phosphorylation and Alzheimer\'s disease                                                 11
  2d       hsa00190; hsa05012                       Oxidative phosphorylation and Parkinson\'s disease                                                 11
  2e       hsa05010; hsa05016                       Alzheimer\'s disease and Huntington\'s disease                                                     11
  2f       hsa00190; hsa05016                       Oxidative phosphorylation and Huntington\'s disease                                                11
                                                                                                                                                       
  3a       hsa00190; hsa05012; hsa05016             Oxidative phosphorylation, Parkinson\'s disease, and Huntington\'s disease                         11
  3b       hsa00190; hsa05010; hsa05016             Oxidative phosphorylation, Alzheimer\'s disease, and Huntington\'s disease                         11
  3c       hsa00190; hsa05010; hsa05012             Oxidative phosphorylation, Alzheimer\'s disease, and Parkinson\'s disease                          11
  3d       hsa05010; hsa05012; hsa05016             Alzheimer\'s disease, Parkinson\'s disease, and Huntington\'s disease                              11
                                                                                                                                                       
  4a       hsa00190; hsa05010; hsa05012; hsa05016   Oxidative phosphorylation, Alzheimer\'s disease, Parkinson\'s disease, and Huntington\'s disease   11
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